Skip to main content

Table 2 Study-agent related adverse events

From: Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial

Adverse Event Grade 1 Grade 2 Grade 3–4
Injection Site Pain 10 0 0
Headache 6 0 0
Fatigue 6 1 0
Anorexia 1 1 0
Fever 2 0 0
Nausea 3 2 0
Rash 2 0 0
Infection 0 0 0
Respiratory 1 0 0
Hepatic 2 0 0
Thrombocytopenia 1 0 0
Anemia 1 0 0
Infection 1 0 0